Structure Therapeutics(US:GPCR) Globenewswire·2026-02-26 21:02Core Insights - Structure Therapeutics has reported positive results from the aleniglipron Phase 2 ACCESS programs, showing significant weight loss of up to 15.3% at 36 weeks [1][7] - The company is well-positioned to capture market share in the obesity treatment sector with its novel oral small molecule therapeutics [2] - Structure Therapeutics has a strong financial position with $1.4 billion in cash and equivalents, expected to fund operations through the end of 2028 [1][9] Clinical Development - Aleniglipron, an oral small molecule GLP-1 receptor agonist, is advancing to Phase 3 clinical development, with initiation expected in the second half of 2026 [1][5] - The upcoming 44-week data from the ACCESS II study is anticipated in Q1 2026, which will provide a more comprehensive profile of aleniglipron [2][4] - Initial data from the ongoing Phase 1 study of ACCG-2671 and the Phase 1 initiation of ACCG-3535 are expected in the second half of 2026 [1][15] Financial Performance - Research and Development (R&D) expenses for Q4 2025 were $68.7 million, up from $33.5 million in Q4 2024, reflecting increased clinical trial costs and personnel expenses [10] - General and Administrative (G&A) expenses for Q4 2025 were $17.6 million, compared to $13.6 million in Q4 2024, primarily due to increased employee expenses [11] - The company reported a net income of $33.0 million for Q4 2025, contrasting with a net loss of $36.5 million in Q4 2024 [14] Market Position - The obesity market is increasingly favoring new oral treatment options, and Structure Therapeutics aims to leverage this trend with its innovative therapies [2] - The company has completed a $748 million financing, strengthening its financial position to advance its clinical programs [2] - Structure Therapeutics is developing a broad portfolio of oral small molecules, including amylin receptor agonists, to address unmet medical needs in metabolic diseases [16][17]